Argenx reported strong Q2 product net sales of $1.5 billion, a 60% increase year-over-year, driven by robust sales of its autoimmune treatment Vyvgart. RBC Capital raised its price target for Argenx stock to $1,025 from $945 and maintained an Outperform rating, reflecting confidence in the company's consistent growth and alignment with its Vision 2030 plan. This marks Argenx's 18th consecutive quarter of growth, highlighting its expanding market presence. The stock gained 8.56% to trade at $924.60, with a market cap of about $57.5 billion.
Quest Diagnostics reported a 10.2% revenue increase to $3.04 billion in Q2 2026, driven by a 10% rise in organic revenue and a 13.1% volume increase. Adjusted EPS rose to $3.12, beating analyst expectations of $2.83. Due to strong demand and successf...
HSBC initiated a 'Hold' rating on SpaceX (NASDAQ:SPCX) with the stock at $118.24 amid market volatility following its June IPO. The upcoming lock-up expiry on August 4 will increase the public float from 4.9% to about 12%, potentially pressuring the ...
Intel reported strong Q1 results with earnings per share of $0.42, doubling analyst estimates of $0.21, and revenue of $16.13 billion, a 25% increase year-over-year. This marks Intel's fastest revenue growth since 2011, fueled by rising demand in dat...
Charter Communications anticipates a 1.77% decline in Q2 2026 revenue to $13.52 billion, reflecting challenges in broadband, mobile growth, and video customer losses. Despite this, earnings per share (EPS) are projected to increase by 10.78% to $10.1...
Univest Securities, a New York-based investment bank, ranked 5th in the Q2 2026 U.S. PIPE and Private Placement markets by number of transactions, completing 23 deals and raising about $198.1 million. This marks their second consecutive quarter in th...
